Peps
What is Triptorelin?
Triptorelin is a GnRH agonist used for hormone suppression in clinical settings. The featured breast-cancer analysis included several ways of achieving ovarian suppression.
Biological role or research focus
Ovarian suppression in hormone-sensitive cancer.
The randomized contrast was between endocrine-treatment strategies. Because ovarian suppression had multiple methods, the outcome difference cannot be attributed to triptorelin alone.
Role reference: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
- Class / identity
- GnRH receptor agonist
- Research focus
- Ovarian suppression in hormone-sensitive cancer
- Featured evidence
- Human randomized combination-treatment trials
- Source check
- October 4, 2026
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Molecular structure
How Triptorelin works
Sustained GnRH agonist exposure can suppress reproductive-hormone signaling. Its clinical effect differs from short-term or pulsatile stimulation of the same general pathway.
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Medicine status & clinical context
Triptorelin is a prescription GnRH agonist with product-dependent uses in prostate cancer and central precocious puberty. The breast-cancer endocrine strategy summarized here is a separate study context and does not isolate the effect of triptorelin from all accompanying treatments.
The featured evidence concerns ovarian suppression alongside endocrine therapy in premenopausal hormone-receptor-positive early breast cancer. It is not a trial isolating triptorelin’s effect.
Source: MedlinePlus · Triptorelin injection ↗
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized combination-treatment trials · 2014
Combined TEXT / SOFT analysis
How did two endocrine strategies compare when both included ovarian suppression?
- Population / model
- 4,690 premenopausal women with hormone-receptor-positive early breast cancer in the combined analysis.
- Study design
- Randomized comparison of exemestane plus ovarian suppression with tamoxifen plus ovarian suppression. Suppression was achieved using triptorelin, surgery, or irradiation.
- Main finding
- Five-year disease-free survival was 91.1% versus 87.3%: hazard ratio 0.72. Overall survival was not significantly different.
- Limits & context
- The randomized contrast was between endocrine-treatment strategies. Because ovarian suppression had multiple methods, the outcome difference cannot be attributed to triptorelin alone.
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Triptorelin. ↗
· 2012 · Review
Triptorelin embonate (6-month formulation). ↗
Drugs · 2010 Feb 12 · Journal Article, Review
An overview of treatments for endometriosis. ↗
JAMA · 2015 Jan 20 · Journal Article, Research Support, Non-U.S. Gov't, Review
Triptorelin for the treatment of endometriosis. ↗
Expert opinion on pharmacotherapy · 2014 Jun · Journal Article, Review
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
What the featured evidence can tell us
Ovarian suppression changes sex-hormone exposure and requires indication-specific clinical monitoring. The combination trial does not isolate the safety of triptorelin from other treatment components.
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Identity, route, and evidence limits
The randomized contrast was between endocrine-treatment strategies. Because ovarian suppression had multiple methods, the outcome difference cannot be attributed to triptorelin alone.
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Official product context · checked October 4, 2026
An early hormone increase can temporarily worsen symptoms. The medication reference also discusses metabolic changes and clinical monitoring during longer treatment.
Source: MedlinePlus · Triptorelin injection ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
1 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Biohackingturkey
Triptorelin Asetat Nedir? 5 Dakikada Öğrenin! ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Can the benefit be attributed to triptorelin alone?
- What population, comparator, and route were actually studied?
- The randomized contrast was between endocrine-treatment strategies. Because ovarian suppression had multiple methods, the outcome difference cannot be attributed to triptorelin alone.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Can the benefit be attributed to triptorelin alone?
No. Both groups received ovarian suppression through different permitted methods. The randomized comparison concerned the accompanying endocrine therapies.
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.